DOJ alleges whistleblower part of fraud scheme
Pharma Compliance Alert, October 31, 2007
The man who blew the whistle on Cell Therapeutics is now under investigation by the Department of Justice (DOJ) for allegedly masterminding an even bigger fraud scheme within Cell Therapeutics.
James Marchese, a former sales representative for Cell Therapeutics, told the DOJ that his former employer had fraudulently marketed Trisenox, a cancer drug, and defrauded Medicare for millions of dollars. In April, Cell Therapeutics settled its case for $10.5 million. Marchese was in line to receive up to $2.8 million for bringing the fraud to light.
The DOJ is asking a federal judge in Seattle to award Marchese nothing because the DOJ contends he created the bigger fraud scheme at the core of the case. Prosecutors contend Marchese engineered a complex scheme to mislead oncologists and Medicare into believing that Trisenox had been approved to treat more types of cancer than it was. Marchese denies the allegations.
Click here to more about this story in The New York Times.
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- Capturing all necessary codes for IUD insertion and removal can be challenging
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- What does case-mix index mean to you?
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- HIPAA Q&A: Level of encryption needed for email
- Searched